CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report)’s share price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.85 and traded as high as $4.08. CAMP4 Therapeutics shares last traded at $3.86, with a volume of 108,509 shares trading hands.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on CAMP shares. Wall Street Zen upgraded CAMP4 Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Needham & Company LLC started coverage on CAMP4 Therapeutics in a report on Thursday, October 15th. They set a “buy” rating and a $8.00 target price on the stock. Raymond James Financial started coverage on CAMP4 Therapeutics in a research report on Friday, October 23rd. They set a “strong-buy” rating and a $10.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Tuesday, September 29th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $10.44.
Get Our Latest Stock Analysis on CAMP
CAMP4 Therapeutics Stock Up 1.6%
The stock has a fifty day moving average of $3.85 and a 200-day moving average of $4.20. The firm has a market capitalization of $242.22 million, a P/E ratio of -1.80 and a beta of 0.28.
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last released its earnings results on Thursday, November 5th. The Wireless communications provider reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.17). CAMP4 Therapeutics had a negative net margin of 2,276.33% and a negative return on equity of 182.39%. The business had revenue of $1.90 million during the quarter. Sell-side analysts predict that CAMP4 Therapeutics Corporation will post -0.78 EPS for the current fiscal year.
Insiders Place Their Bets
In other CAMP4 Therapeutics news, CFO Kelly Gold purchased 10,000 shares of the business’s stock in a transaction on Monday, August 31st. The stock was acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the acquisition, the chief financial officer directly owned 10,000 shares of the company’s stock, valued at $39,600. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Andrew J. Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the sale, the director directly owned 2,033,270 shares of the company’s stock, valued at $8,214,410.80. The trade was a 16.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 593,613 shares of company stock valued at $2,504,037. Corporate insiders own 21.69% of the company’s stock.
Hedge Funds Weigh In On CAMP4 Therapeutics
Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at approximately $78,000. Deutsche Bank AG bought a new stake in shares of CAMP4 Therapeutics in the second quarter valued at approximately $138,000. Empowered Funds LLC acquired a new stake in CAMP4 Therapeutics during the third quarter worth approximately $220,000. Landscape Capital Management L.L.C. acquired a new stake in CAMP4 Therapeutics during the third quarter worth approximately $264,000. Finally, Bank of New York Mellon Corp acquired a new stake in CAMP4 Therapeutics during the second quarter worth approximately $365,000.
CAMP4 Therapeutics Company Profile
CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.
Featured Articles
- Five stocks we like better than CAMP4 Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
